Vertex named a premier, inc. breakthroughs innovation celebration winner for journavx™, a first-in-class non-opioid treatment for adults with moderate-to-severe acute pain

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that it has been named a 2025 breakthroughs innovation celebration winner by premier, inc., a leading health care improvement company. the honor recognizes journavx™ (suzetrigine), an oral, non-opioid, highly selective nav1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology. “we are honored to be recognized at premier's 2025.
VRTX Ratings Summary
VRTX Quant Ranking